+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
ID06446128

Study of CD19CD22BCMA CAR-T Cell Therapy for Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Led by Shanghai Cell Therapy Group Co.,Ltd · Updated on 2025-08-21

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating CD19CD22BCMA chimeric antigen receptor T CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma. This early phase 1, single arm, open-label study aims to assess the safety and tolerability of this treatment and determine the highest dose patients can safely receive. Additional goals include studying how the CAR-T cells behave in the body and their effect on patient survival. Participants will undergo several phases including screening, cell collection apheresis, lymphodepletion with chemotherapy drugs cyclophosphamide and fludarabine, followed by a single intravenous infusion of the CAR-T cells. Safety and dose-limiting toxicities will be monitored from day 1 to day 28 after infusion. After this, patients will be followed for longer-term effects and outcomes until the study ends. During the study, patients will have regular evaluations including blood tests to measure CAR-T cell levels, cytokines, and drug pharmacokinetics. Survival and disease progression will be tracked for up to two years. The entire process includes careful monitoring for side effects and treatment response, with visits and assessments scheduled throughout the treatment and follow-up periods.

CONDITIONS

Brief Title

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Research Team

J

Jinxing Lou

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here